January 5th 2025The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on treatment choices for gastric adenocarcinoma and ctDNA monitoring and clearing in HER2-positive breast cancer.
